Home

Home

article image

Better records reveal more bugs

Clostridium difficile has killed more patients than MRSA

UK - According to new figures obtained from death certificates by the Office for National Statistics (ONS) deaths involving Clostridium difficile rose by 69% to 3,800 in the 2004-05 period, whilst MRSA increased by 39% to 1,629. (In two hospitals in one city, C. difficile was linked to the deaths of 12 patients in just four weeks and, in another city, in one eight-month period, at least 49 people died after catching C. difficile).

Although the bacteria were mentioned on the death certificates, the ONS pointed out that does not mean they were the actual cause of death.

In addition, this apparent increase in cases might be due to greater public awareness of Clostridium difficile, and so an increase in recording its presence on the certificates, the ONS suggested. 

Lord Hunt, the British Health Minister, agreed with this possibility, but said it nonetheless remains ‘…a major challenge for the NHS and a top priority for government’. However, he added that tough hygiene targets showed that the NHS is beginning to see significant reductions in MRSA infections.
C. difficile, lives up to its ‘difficult’ name. Alcohol hand rubbing and other measures that combat MRSA appear to have little effect on these bacteria, which produce spores that become airborne, and can survive well on surfaces for some time. However, vigorous disinfectant cleansing of affected environments and the hands of hospital staff is effective. 

From the death certificates it was seen that most of them, from both types of bacteria, were of older patients.

This article was published on 03/08/2007

Search

 

Service

Company News

Accu-Chek® Combo – put effective diabetes management into action

At the annual congress of the European Association for the Study of Diabetes (EASD) this year in Rome, Roche Diabetes Care introduced Accu-Chek Combo – the insulin pump system that combines an insulin pump with an intelligent glucose monitoring system, a bolus calculator, and an integrated pump remote-control.

Insulin in oral capsules

At the international congress on diabetes in September, Oramed Pharmaceuticals, Inc. introduced its oral insulin capsules that might in the future replace injections patients currently have to face. Last week Oramed announced the agreement with ETI Karle Clinical Pvt. Ltd. to conduct phase 2B clinical trials for its oral insulin capsules.

Carestream: technical infrastructure for EU funded R-bay project

Carestream Health is a major technical infrastructure provider to the EU-funded R-Bay validation project, which aims to address the uneven spread of radiologists across member states. CARESTREAM Radiology and Information Management Solutions are driving the initial test platform for the project by facilitating remote reporting of images from hospitals in Denmark, Finland and Czech Republic by clinical providers in Estonia, Lithuania and the Netherlands.